Article info
PDFClinical science
A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration
- Correspondence to Dr Rajendra S Apte, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, 660 South Euclid Avenue, Box 8096, St Louis, MO 63110, USA; apte{at}vision.wustl.edu
Citation
A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration
Publication history
- Received April 6, 2015
- Revised September 9, 2015
- Accepted October 1, 2015
- First published October 29, 2015.
Online issue publication
June 21, 2016
Article Versions
- Previous version (29 October 2015).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/